Moberg Pharma AB (publ) (MOB.ST)
SEK 11.28
(10.37%)
SEK 11.28
(10.37%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -1.33 SEK | 3.62% |
| 2022 | -1.38 SEK | 43.21% |
| 2021 | -2.43 SEK | 62.67% |
| 2020 | -6.51 SEK | 0.0% |
| 2018 | 6.39 SEK | 16.82% |
| 2017 | 5.47 SEK | -71.78% |
| 2016 | 19.38 SEK | 26.09% |
| 2015 | 15.37 SEK | 87.44% |
| 2014 | 8.20 SEK | 195.24% |
| 2013 | -8.61 SEK | -126.19% |
| 2012 | 32.87 SEK | 569.57% |
| 2011 | -7.00 SEK | 83.86% |
| 2010 | -43.37 SEK | 42.93% |
| 2009 | -75.99 SEK | 39.74% |
| 2008 | -126.11 SEK | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -0.13 SEK | 43.48% |
| 2024 Q1 | -0.23 SEK | 0.0% |
| 2023 Q3 | -0.36 SEK | -38.46% |
| 2023 Q1 | -0.34 SEK | -61.9% |
| 2023 FY | - SEK | 3.62% |
| 2023 Q2 | -0.26 SEK | 23.53% |
| 2023 Q4 | -0.23 SEK | 36.11% |
| 2022 Q2 | -0.06 SEK | 37.26% |
| 2022 Q1 | -0.10 SEK | 26.92% |
| 2022 FY | - SEK | 43.21% |
| 2022 Q3 | -0.04 SEK | 28.69% |
| 2022 Q4 | -0.21 SEK | -394.12% |
| 2021 FY | - SEK | 62.67% |
| 2021 Q4 | -0.13 SEK | 85.39% |
| 2021 Q1 | 4.54 SEK | 238.41% |
| 2021 Q2 | -0.75 SEK | -116.52% |
| 2021 Q3 | -0.89 SEK | -18.67% |
| 2020 FY | - SEK | 0.0% |
| 2020 Q1 | -1.76 SEK | 17.76% |
| 2020 Q4 | -3.28 SEK | -36.67% |
| 2020 Q2 | -2.71 SEK | -53.98% |
| 2020 Q3 | -2.40 SEK | 11.44% |
| 2019 Q4 | -2.14 SEK | -114.16% |
| 2019 Q1 | 276.06 SEK | 49196.43% |
| 2019 Q3 | 15.11 SEK | 5496.43% |
| 2019 Q2 | -0.28 SEK | -100.1% |
| 2018 Q2 | 2.31 SEK | 126.47% |
| 2018 FY | - SEK | 16.82% |
| 2018 Q4 | 0.56 SEK | -45.1% |
| 2018 Q3 | 1.02 SEK | -55.84% |
| 2018 Q1 | 1.02 SEK | 108.16% |
| 2017 Q3 | 6.06 SEK | 259.06% |
| 2017 FY | - SEK | -71.78% |
| 2017 Q1 | -1.47 SEK | -880.0% |
| 2017 Q4 | 0.49 SEK | -91.91% |
| 2017 Q2 | -3.81 SEK | -159.18% |
| 2016 FY | - SEK | 26.09% |
| 2016 Q1 | -3.40 SEK | -13809.68% |
| 2016 Q2 | 16.82 SEK | 594.71% |
| 2016 Q3 | 7.68 SEK | -54.34% |
| 2016 Q4 | -0.15 SEK | -101.95% |
| 2015 FY | - SEK | 87.44% |
| 2015 Q1 | 6.66 SEK | 39980.24% |
| 2015 Q3 | 5.38 SEK | 61.56% |
| 2015 Q2 | 3.33 SEK | -50.0% |
| 2015 Q4 | 0.02 SEK | -99.54% |
| 2014 Q4 | -0.02 SEK | -100.63% |
| 2014 Q2 | 2.82 SEK | -2.76% |
| 2014 Q1 | 2.90 SEK | 8968.5% |
| 2014 FY | - SEK | 195.24% |
| 2014 Q3 | 2.65 SEK | -6.03% |
| 2013 FY | - SEK | -126.19% |
| 2013 Q4 | -0.03 SEK | 98.88% |
| 2013 Q3 | -2.91 SEK | 13.39% |
| 2013 Q2 | -3.36 SEK | -54.84% |
| 2013 Q1 | -2.17 SEK | 59.89% |
| 2012 Q2 | 1.28 SEK | -96.41% |
| 2012 Q1 | 35.69 SEK | 753.83% |
| 2012 FY | - SEK | 569.57% |
| 2012 Q4 | -5.41 SEK | -304.15% |
| 2012 Q3 | 2.65 SEK | 107.03% |
| 2011 Q2 | -11.99 SEK | -29.06% |
| 2011 Q4 | 4.18 SEK | -18.36% |
| 2011 Q3 | 5.12 SEK | 142.7% |
| 2011 Q1 | -9.29 SEK | -258.69% |
| 2011 FY | - SEK | 83.86% |
| 2010 Q1 | -13.12 SEK | 0.0% |
| 2010 FY | - SEK | 42.93% |
| 2010 Q3 | -26.22 SEK | -134.32% |
| 2010 Q4 | -2.59 SEK | 90.12% |
| 2010 Q2 | -11.19 SEK | 14.71% |
| 2009 FY | - SEK | 39.74% |
| 2008 FY | - SEK | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| AcuCort AB | -0.16 SEK | -731.25% |
| AlzeCure Pharma AB (publ) | -0.60 SEK | -121.667% |
| BioGaia AB (publ) | 3.62 SEK | 136.74% |
| Enzymatica AB (publ) | -0.28 SEK | -375.0% |
| Enorama Pharma AB (publ) | -1.61 SEK | 17.391% |
| Gabather AB (publ) | -0.65 SEK | -104.615% |
| Klaria Pharma Holding AB (publ.) | -0.36 SEK | -269.444% |
| Nanexa AB (publ) | -1.09 SEK | -22.018% |
| Newbury Pharmaceuticals AB (publ) | -0.72 SEK | -84.722% |
| ODI Pharma AB | 0.02 SEK | 5783.761% |
| Orexo AB (publ) | -3.73 SEK | 64.343% |
| Probi AB (publ) | 1.48 SEK | 189.865% |
| Swedencare AB (publ) | 0.37 SEK | 459.459% |
| Swedish Orphan Biovitrum AB (publ) | 7.47 SEK | 117.805% |
| Toleranzia AB | -0.06 SEK | -2275.0% |
| Vivesto AB | -0.74 SEK | -79.73% |